Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Legislation (77)
- Safety monitoring and information (41)
- Advertising (25)
- Manufacturing (19)
- Labelling and packaging (17)
- COVID-19 (15)
- Vaping hub (13)
- Compliance and enforcement (7)
- Scheduling (national classification system) (6)
- Import and export (2)
- Sunscreens (2)
- Clinical trials (1)
- Committees and advisory bodies (1)
- Medicinal cannabis hub (1)
- Urogynaecological (transvaginal) surgical mesh hub (1)
Search
334 result(s) found, displaying 101 to 125
-
Safety updatesBe alert to new warnings of romosozumab (Evenity) cardiovascular risks for patients with a history of heart attack or stroke. If you're a health professional, read our Medicine safety update.
-
Safety updatesIf you're a health professional, get the latest information about medicines with safety related updates to their Product Information.
-
Regulatory decision noticesWe've granted a labelling exemption for the COVID-19 Vaccine, Pfizer (raxtozinameran), under the current Poisons Standard.
-
Regulatory decision noticesFind out how listed medicine ingredients, and requirements for their use, have been updated in the Therapeutic Goods (Permissible Ingredients) Determination (No. 4) 2023.
-
Safety updatesRecent coronial inquiries have highlighted the need for health professionals to be alert to the well documented risk of overdose with baclofen.
-
Safety updatesMedicines Safety Update - Information for health professionals
-
Regulatory decision noticesArrangement under subsection 7C(1) of the Therapeutic Goods Act 1989
-
Safety updatesMedicines Safety Update - Information for health professionals
-
Regulatory decision noticesThis instrument is made under subregulation 10JD(4) of the Therapeutic Goods Regulations 1990.
-
Safety updatesMedicines Safety Update - Information for health professionals
-
Safety updatesUnderstand the Medicines Safety Update for July 2023 - Information for health professionals and consumers.
-
Regulatory decision noticesFind out how listed medicine ingredients, and requirements for their use, have been updated in the latest Therapeutic Goods (Permissible Ingredients) Determination.
-
Safety updatesUnderstand the Medicines Safety Update for June 2023 - Information for health professionals and consumers.
-
Regulatory decision noticesThe TGA has provisionally approved Pfizer’s bivalent COVID-19 vaccine, tozinameran and riltozinameran (COMIRNATY Original/Omicron BA.1) for use as a booster dose in adults 18 years and over.
-
Safety updatesMedicines Safety Update - Information for health professionals
-
Safety updatesA warning about anticoagulant-related nephropathy (ARN) has been added to the Product Information (PI) for all oral anticoagulants.
-
Regulatory decision noticesArrangement under subsection 7C(1) of the Therapeutic Goods Act 1989
-
Regulatory decision noticesArrangement under subsection 7C(1) of the Therapeutic Goods Act 1989
-
Regulatory decision noticesDelays in processing timeframes of applications to extend GMP Clearances.
-
Safety updatesNew warnings for baricitinib, tofacitinib and upadacitinib follow a TGA review of a randomised safety trial called the ORAL Surveillance Study.
-
Safety updatesMedicines Safety Update - Information for health professionals
-
Regulatory decision noticesListed medicine ingredients and requirements for their use have been updated in the Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2023.
-
Safety updatesMedicines Safety Update - Information for health professionals
-
Regulatory decision noticesMore applications for Good Manufacturing Practice (GMP) clearances can now be assessed under the TGA’s MRA pathway.
-
Safety updatesHealth professionals should check if patients undergoing general anaesthesia have used products containing pholcodine in the previous 12 months.